The FTSE 100 surged on Monday as a strong start to the trading session was boosted by a positive update from a US company working on a COVID-19 vaccine. The morning had started with optimism around the reopening of economies which was accentuated when US-based Moderna said they have received positive early signs from a coronavirus vaccine trial. “These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg,” said Tal Zaks, Chief Medical Officer at Moderna. “When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.” “With today’s positive interim Phase 1 data and the positive data in the mouse challenge model, the Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July and, if successful, file a BLA,” said Stéphane Bancel, Chief Executive Officer at Moderna. “We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2.” Despite the positive update from Moderna, the vaccine still has a number hurdles to full approval and a global roll out will take many months, even if it is approved. Nonetheless, equity markets soared on the news. Connor Campbell, analyst and Spreadex noted: “Vaccine news is sort of the holy grail of market-boosters at the moment, even if headlines often obscure the timelines regarding the production of such preparations,” said Connor Campbell “The Dow Jones galloped out of the date, greedily taking back 670 points. That was enough to lift the index past 24350, around 1400 points off of the lows incurred last Thursday.” “In turn this transformed a very strong European session into something more spectacular. A 200 point surge for the FTSE saw it touch its fingers to 6000, while a giddy 4.6% increase for the DAX sent the German bourse back above 10900.” The FTSE 100 was trading above 6,000 as we moved towards the close in London.

The FTSE 100 halted a two-day decline on Friday as share rose tentatively as markets moves toward the end of choppy week for markets. The FTSE 100 fell sharply on Thursday as investors became sceptical about the validity of a market rally during one of the worst recessions in history. The scale of the economic downturn was again visible in the US weekly jobless claims released on Thursday as nearly 3 million people lost their jobs in the last week. However, China produced more promising data over night casting a wave of optimism in equity markets on Friday. Chinese industrial production rose 3.9% year-on-year in the month of April as factories reopened following months of lockdowns. “News that China came out relatively okay in industrial production, that’s a big part of it. China resuming business even though it might be slow has given some confidence,” said Per Hammarlund, chief Emerging Market strategist at SEB. The news helped buoy commodity prices and equities followed with miners Glencore, Rio Tinto, Anglo American and BHP Group all stronger on the day. The FTSE 100 was 0.8% higher at 5,790 just after midday in London whilst the German Dax was up 0.9% to 10,430. Hargreaves Lansdown was also one of the top risers, up over 4%, a day after the wealth management company released a jump in activity throughout the coronavirus crisis volatility. BT was top of the pile on Friday lunchtime after the FT reported the embattled telecoms group said it was in talks to dispose of a stake in Openreach. BT Group have recently scrapped their dividend as part of a strategic move to focus on 5G and Fibre. There was also good news in the fight against COVID-19 from the UK’s small caps as Avacta announced progress in the development of a potential treatment. Their Affirmer technology has been found to show promising signs in blocking the path of the COVID-19 infection.

Shares in London-listed biotech company Avacta (LON:AVCT) surged on Friday after the group announced progress in their development of a treatment for COVID-19. Avacta said that they had discovered their Affrimer technology had blocked the interaction of the coronavirus infection with human cells which is a key pathway for the virus. The Avacta share price had leapt over 30% by mid morning on Friday to trade at 140p. Avacta shares are up 700% in 2020, making them one of the best performers on London exchanges so far in 2020. The company’s Affirmer technology has been the driving force behind the rise with initial applications in COVID-19 testing now potentially providing a vitally important treatment. Analysts also noted the possibility for a deal with large pharmaceutical companies could be a material development for the treatment and Avacta themselves. “Beyond the obvious reputational and commercial, albeit presently wholly unquantifiable, short and longer-term opportunities that could emerge from Avacta’s partnerships with Cytiva and Adeptrix, potential now to also partner with Big Pharma in an effort to develop a globally significant coronavirus neutralising technology, suggests a further major inflection point and opportunity for the creation of significant near-term value for shareholders,” noted Barry Gibb, Research Analyst of Tuner Pope Investments to the UK Investor Magazine. “Alongside this, the Group also continues to forward its other exciting developments and partnered programmes plus licensing relationships for its diagnostics reagents,” Mr Gibb concluded. The Avacta CEO outlined the progress Avacta had made with the treatment that seeks the block interaction with the virus. “This is a very exciting development in the COVID-19 programme. It only took four weeks to generate more than fifty Affimer reagents that bind the SARS-COV-2 virus spike protein and amongst those we now know that there are neutralising Affimers that block the interaction with a key human cell surface receptor, raising the potential for a therapy to prevent infection,” said Dr Alastair Smith, Chief Executive Officer of Avacta Group. He continued to explain the attention the wider industry was paying to this particular type of COVID-19 therapy. “Recently GSK invested $250 million in Vir Biotechnology Inc3 to develop potential antibody treatments for COVID-19 by selecting antibodies from recovered patients, and AstraZeneca also recently announced that it would start a programme to find new monoclonal antibodies that block the spike/ACE2 interaction4.” “There is significant potential for a therapy that could help prevent infection and limit the progression of the disease, providing immediate benefit to patients. With a large and well-resourced partner, a neutralising Affimer therapy could potentially be developed more quickly than a vaccine and we believe that the likelihood of success would be high.” “I look forward to updating the market further on this and on the development of a COVID-19 antigen rapid saliva test with Cytiva which continues apace.”

Novacyt (LON:NYCT) shares fell on Thursday after the clinical diagnostics company provided outlook for 2020 and reported a strong increase in cash levels through 2020. Novacyt shares were down 11% on Thursday but are up over 2,600% in 2020. The Novacyt share price closed out 2019 trading at just 12p and have reached intraday highs above 500p in the last month. The astronomical rise was sparked by Novacyt’s provision of testing kits for COVID-19, having won approval from the FDA and secured orders from Public Health England. The outlook for 2020 was included in the full year results which highlighted a £6.5m loss for 2019. However, the loss was for the 12 months to 31st December, and doesn’t represent any activity from COVID-19 testing. Investors may have been disappointed with the outlook as there wasn’t any guidance on potential sales in revenue terms, although the company did say they expected to be producing at an ‘output rate of more than ten million tests per month’ from June 2020. As an indication of the impact of the COVID-19 testing kits on Novacyt’s business so far in 2020, cash had increased from €1.8 million at the end of 2019 to €9.2 million at the end of April 2020. “2019 was a year of consolidation as we completed the refinancing and restructure of the business, positioning Novacyt to resume its three-pillar growth strategy of organic, R&D and acquisitive growth,” said Graham Mullis, Group CEO of Novacyt. “Following the rapid development and successful launch of one of the world’s first molecular tests for COVID-19, we expect 2020 to be transformational for the business in almost every way based upon visibility of current sales and continued significant demand for the test,” Mullis continued. “Supported by Novacyt’s core strengths of in vitro diagnostics product development, commercialisation and contract manufacturing, we believe the Company’s stronger financial position and enhanced reputation will be the catalyst in creating a leading global clinical diagnostics business in infectious diseases.” “I would like to extend my sincere gratitude to all of our employees for their ongoing hard work and dedication, as well as our partners and suppliers for their loyalty throughout 2019 and so far in 2020 in the fight against COVID-19. Finally, I would like to thank our shareholders, long- standing and new, who continue to support Novacyt.”

The Lloyds share price (LON:LLOY) was fully involved in the rebound rally from the low point in March, having rallied from 27.9p to 34.6p, a gain of over 20%. The rally in Lloyds and other UK banks was sparked by optimism surrounding the reopening of economies and a consistent drop in the number of new coronavirus cases, which brought the pandemic under control. However, Lloyds shares have since resumed their decline as investors digest the economic impact of coronavirus in the first quarter and what it could mean for second quarter activity. There was an initial consensus the global economy would experience a V-shaped recovery, but with UK GDP falling 5.8% in April alone, a sharp rebound looks unlikely in the short term. There is also the risk of a second wave of coronavirus that could lead to a return to strict lockdown measures. “Talk of a V-shaped recovery feels like wishful thinking, and we expect prolonged periods of depressed growth across the majority of the economy. A flatter, U-shaped recovery is more likely,” said Stefan Koopman an economist at Rabobank. The acceptance of a longer, flatter, economic recovery can be attributed as reason for the recent drop in stocks that has seen the FTSE 100 drop from intraday highs around 6,200 to 5,760.

Lloyds share price

The drop in the wider FTSE 100 benchmark saw Lloyds shares dragged down with it as they headed back down to 28p, and the March low. The prospect of a slow recovery in the economy will ultimately mean Lloyds profitability will take longer to return to pre-crisis levels. The approval of mortgages is likely to be severely impaired through 2020 and generally reduced consumer confidence will impact Lloyds banking activity. However, this is not to say that the lower levels of activity will last forever, and investors could see the current drop in Lloyds shares as an opportunity to pick some up, if they missed the initial sell off below 30p. The unprecedented support from the UK government has averted a complete collaspse in the economy and ensured many in the UK have the income to support activity. In addition, many households would have saved during the lockdown and created pent up demand which is likely to be unleashed on the economy as restrictions lift further. This may come in the form of increased consumer spending, business activity and housing transactions, all of which benefit Lloyds. Whether this take place in the third quarter of 2020 or first quarter of 2021, economic activity will return and provide upside pressure for Lloyds share price. There is also the prospect for a return to dividends in 2021 which will be highly anticipated by the market.

Hargreaves Lansdown (LON:HL) shares jump on Thursday as the wealth management platform said they had experienced recorded dealing figures through the coronavirus crisis. Hargreaves Lansdown announced clients numbers grew by 94,000 to 1,386,000 active clients. The increase in new clients brought in £4 billion in net new business which was up from £2.9 billion in the same period a year ago. The increase in clients activity at Hargreaves Lansdown echoed performance from other online trading and investment platforms such as IG Group, who also recorded record activity through the spread of the pandemic. Hargreaves Lansdown share were up over 8% in early trade on Thursday before falling back and are still down over 11% in 2020. “During this exceptionally volatile and challenging period, Hargreaves Lansdown has performed strongly, adding 94,000 net new clients and £4.0 billion of net new business,” said Chris Hill, Chief Executive Officer of Hargreaves Lansdown. He continued to highlight the investment Hargreaves had made into the business and the impact it was now having. “The investment that we have deliberately undertaken over the past three years into our service, its scalability, our marketing and our technology has enabled us to support and protect the interests of our clients throughout the COVID-19 crisis.” “In these challenging times, it is critical we can support people in managing their investments and savings according to their desired outcomes.” However, Mr Hill cautioned on the outlook for markets as the prospect much touted V-shaped recovery in economies and stock markets fades. “There remains much uncertainty in the coming months and hence, like many businesses, we cannot predict levels of new business or client activity. However, we are confident that the strategy we have invested in, with our focus on the needs of UK investors and savers and delivering the highest level of client service, means that we are well positioned to deliver continued attractive long-term growth.”

Greatland Gold (LON:GGP) have been one of the true success stories of 2020 with share rising over 370% since the beginning of the year. The main factor behind the meteoric rise is the success of the Havieron drilling programme in Western Australia which has yielded a string of successful results. Greatland Gold have a farm-in agreement with Newcrest and there are plans for further drilling over the next 12 months and investors are awaiting the next set of results from the project which may provide the catalyst for upside in the share price. With shares falling back from highs of 9.6p and building a base around 7p-7.5p , it appears profit taking is diminishing and the market has agreed on a fair value as it awaits further updates. With the company not yet receiving revenue, projects are being funded by existing cash reserves which have been boosted since 31st December when the company recorded £4m in cash. This appears ample cash given operating loss was just £2.6m in 2019. Subsequent to the last set of drill results, the CEO of Greatland Gold commented: “We are delighted by the seventh consecutive set of excellent results from Newcrest’s drilling campaign, further demonstrating the robustness and continuity of high-grade mineralisation at Havieron, which remains open to the north west and at depth,” said Gervaise Heddle, Chief Executive Officer of Greatland Gold. “These results represent another important step towards our near-term objective of a maiden resource at Havieron, and further reinforce the potential to accelerate the timetable for commercial production.” Heddle continued to outline the steps taken by Newcrest to ensure the safety of staff but pointed to a possible commencement of testing again in the short term. “We are pleased by the extensive steps taken by Newcrest to mitigate the risks of the COVID-19 pandemic at site, whilst maintaining their ongoing commitment to Havieron with nine drill rigs currently operational. We expect step out drilling along strike and at depth to commence in the near term, which will begin to provide us with a clearer picture of the potential to further extend the zone of high-grade mineralisation at Havieron.”